Akihiko Sato

List of Publications by Year
in descending order

35 papers	1,816 citations	430874 18 h-index	361022 35 g-index
37 all docs	37 docs citations	37 times ranked	2187 citing authors

#	Article	IF	Citations
1	In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor. Antimicrobial Agents and Chemotherapy, 2011, 55, 813-821.	3.2	346
2	In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Research, 2018, 160, 109-117.	4.1	246
3	SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells. PLoS Pathogens, 2021, 17, e1009233.	4.7	162
4	Carbamoyl Pyridone HIV-1 Integrase Inhibitors 3. A Diastereomeric Approach to Chiral Nonracemic Tricyclic Ring Systems and the Discovery of Dolutegravir (S/GSK1349572) and (S/GSK1265744). Journal of Medicinal Chemistry, 2013, 56, 5901-5916.	6.4	161
5	S-1153 Inhibits Replication of Known Drug-Resistant Strains of Human Immunodeficiency Virus Type 1. Antimicrobial Agents and Chemotherapy, 1998, 42, 1340-1345.	3.2	129
6	Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Research, 2008, 80, 213-222.	4.1	100
7	Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection. Antimicrobial Agents and Chemotherapy, 2015, 59, 397-406.	3.2	84
8	The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral. Antimicrobial Agents and Chemotherapy, 2008, 52, 901-908.	3.2	71
9	Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Research, 2009, 81, 141-146.	4.1	50
10	Small Amino Acid Changes in the V3 Loop of Human Immunodeficiency Virus Type 2 Determines the Coreceptor Usage for CXCR4 and CCR5. Virology, 1999, 264, 237-243.	2.4	47
11	A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site. Immunity, 2021, 54, 2385-2398.e10.	14.3	46
12	Effects of Raltegravir or Elvitegravir Resistance Signature Mutations on the Barrier to Dolutegravir Resistance In Vitro. Antimicrobial Agents and Chemotherapy, 2015, 59, 2596-2606.	3.2	33
13	Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models. PLoS ONE, 2019, 14, e0217307.	2.5	33
14	Efficacy of Single Intravenous Injection of Peramivir against Influenza B Virus Infection in Ferrets and Cynomolgus Macaques. Antimicrobial Agents and Chemotherapy, 2011, 55, 4961-4970.	3.2	31
15	Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Scientific Reports, 2019, 9, 3466.	3.3	25
16	In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor. Antiviral Research, 2006, 70, 66-74.	4.1	21
17	Establishment of a cynomolgus macaque model of influenza B virus infection. Virology, 2010, 407, 178-184.	2.4	19
18	Efficacy of Repeated Intravenous Administration of Peramivir against Highly Pathogenic Avian Influenza A (H5N1) Virus in Cynomolgus Macaques. Antimicrobial Agents and Chemotherapy, 2014, 58, 4795-4803.	3.2	19

#	Article	IF	Citations
19	Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors. Antiviral Research, 2018, 152, 1-9.	4.1	19
20	Identification of Compound-B, a novel anti-dengue virus agent targeting the non-structural protein 4A. Antiviral Research, 2018, 155, 60-66.	4.1	19
21	Prevalent Polymorphisms in Wild-Type HIV-1 Integrase Are Unlikely To Engender Drug Resistance to Dolutegravir (S/GSK1349572). Antimicrobial Agents and Chemotherapy, 2013, 57, 1379-1384.	3.2	18
22	MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2. Scientific Reports, 2021, 11, 5376.	3.3	18
23	Efficacy of Repeated Intravenous Injection of Peramivir against Influenza A (H1N1) 2009 Virus Infection in Immunosuppressed Mice. Antimicrobial Agents and Chemotherapy, 2013, 57, 2286-2294.	3.2	14
24	Air-liquid interphase culture confers SARS-CoV-2 susceptibility to A549 alveolar epithelial cells. Biochemical and Biophysical Research Communications, 2021, 577, 146-151.	2.1	14
25	Discovery of novel 5-hydroxy-4-pyridone-3-carboxy acids as potent inhibitors of influenza Cap-dependent endonuclease. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4739-4742.	2.2	11
26	Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets. Vaccine, 2014, 32, 3004-3009.	3.8	10
27	Inhibition of dengue virus infection by 1â€stearoylâ€2â€arachidonoylâ€phosphatidylinositol in vitro. FASEB Journal, 2019, 33, 13866-13881.	0.5	10
28	Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection. Journal of Antimicrobial Chemotherapy, 2021, 76, 189-198.	3.0	10
29	Attenuated infection by a Pteropine orthoreovirus isolated from an Egyptian fruit bat in Zambia. PLoS Neglected Tropical Diseases, 2021, 15, e0009768.	3.0	7
30	The relationship between in vivo antiviral activity and pharmacokinetic parameters of peramivir in influenza virus infection model in mice. Antiviral Research, 2014, 109, 110-115.	4.1	6
31	Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation. Antiviral Research, 2017, 139, 41-48.	4.1	6
32	The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets. Influenza and Other Respiratory Viruses, 2020, 14, 710-719.	3.4	6
33	5-Hydroxymethyltubercidin exhibits potent antiviral activity against flaviviruses and coronaviruses, including SARS-CoV-2. IScience, 2021, 24, 103120.	4.1	6
34	Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection. Viruses, 2022, 14, 111.	3.3	6
35	Identification of quinolone derivatives as effective anti-Dengue virus agents. Antiviral Research, 2020, 184, 104969.	4.1	5